A new assay simply known as The NGAL Test makes it possible to get an earlydiagnosis of acute kidney injury.
Using only a few drops of blood or urine, The NGAL Test, provides results in just 10 minutes and thus addresses the widespread demand for urgent NGAL determination. The NGAL Test is a particle enhanced turbidimetric assay and is designed to run as a user defined reagent on analyzers from Roche, Abbott, Siemens, Olympus and many other manufacturers, effectively giving almost any laboratory access to a fast and easy method to measure NGAL.
The test is now offered with research use only claims, for set-up and local evaluation in countries outside the United States but already from early 2011 The NGAL Test will be available for routine diagnostic use in the EU, and other selected countries. Availability in the United States is contingent upon US FDA clearance.
What is NGAL?
NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal status markers like serum creatinine and shows a proportionate response to injury. NGAL therefore provides a new way to identify patients at risk of developing potentially severe acute kidney injury (AKI) - up to 48 hours before the problem would otherwise be detected.